A new survey being funded by Myeloma UK and carried out by the National Institute for Health and Care Excellence […]
Myeloma UK has launched a new type of Infoday designed exclusively to support the carers, family and friends of myeloma […]
Myeloma UK has launched a new Infopack to provide relapsed and/or refractory patients and their families with the information they […]
Daratumumab (Darzalex®) has been granted an extended licence for use in combination with other myeloma drugs for the treatment of relapsed […]
Many of our supporters joined Myeloma UK in congratulating myeloma patient Jane, who recently celebrated reaching an important milestone since […]
The purpose of the Myeloma XII trial is to see if using a novel drug called ixazomib (Ninlaro®) can strengthen the effect of a second high-dose therapy and stem cell transplant (HDT-SCT).
Myeloma UK is getting ready to attend the 2017 British Society of Haematology’s (BSH) Annual Scientific Meeting, which this year takes place in Brighton. Monica Morris is our Healthcare Professional Manager and is part of the Myeloma UK team attending the conference, “The BSH Annual Meeting attracts leading haematologists from across the UK to discuss the latest developments, not just in myeloma, but across a number of other haematological areas, and is a great opportunity for haematology doctors and nurses to learn about the latest developments in myeloma treatment and care.”